Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Innate Pharma SA ( (FR:IPH) ) has shared an announcement.
On May 13, 2026, Innate Pharma reported its first‑quarter 2026 business update and full‑year 2025 financial results, highlighting progress across its oncology pipeline and a constrained but managed cash position. The company held €25.4 million in cash and financial assets and €20.3 million in financial liabilities as of March 31, 2026, with revenue rising to €2.6 million from collaboration and licensing agreements and an expected cash runway through the end of the third quarter of 2026.
The company confirmed plans to initiate the TELLOMAK‑3 Phase 3 confirmatory trial for lacutamab in cutaneous T‑cell lymphoma in the second half of 2026, contingent on securing non‑dilutive financing via partnering or royalty deals, after receiving U.S. FDA protocol clearance and Breakthrough Therapy Designation for Sézary syndrome in 2025. Innate reported that Phase 1 development of its Nectin‑4 ADC IPH4502 has reached the maximum tolerated dose with ongoing cohort enrichment and preliminary anti‑tumor activity, including in patients relapsed after enfortumab vedotin, supporting its ambition for a differentiated profile in solid tumors.
Pipeline momentum is further supported by AstraZeneca‑led programs, with the PACIFIC‑9 Phase 3 trial of monalizumab in unresectable Stage III non‑small cell lung cancer fully enrolled and heading toward a second‑half 2026 data readout, and IPH5201 showing encouraging pathological complete response rates in the MATISSE Phase 2 lung cancer study presented in April 2026. At the same time, Innate has streamlined its organization through completed layoffs, while partner Sanofi has deprioritized the anti‑BCMA engager SAR’514 but retains development rights, underscoring Innate’s dependence on external partnerships and upcoming clinical catalysts to strengthen its financial and strategic position.
The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR3.10 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma S.A. is a global clinical‑stage biotechnology company focused on developing immunotherapies for cancer patients. Leveraging antibody engineering and novel target identification, it advances a pipeline of potential first‑ or best‑in‑class antibody therapeutics, including the Nectin‑4 antibody-drug conjugate IPH4502 and the anti‑KIR3DL2 antibody lacutamab for cutaneous T‑cell lymphoma.
The company targets areas of high unmet medical need in solid tumors and hematologic malignancies, often in collaboration with large pharmaceutical partners such as AstraZeneca and Sanofi. Its portfolio spans antibody-drug conjugates, checkpoint and metabolic pathway inhibitors, and NK-cell engagers, positioning Innate within the competitive immuno‑oncology space.
Average Trading Volume: 280,604
Technical Sentiment Signal: Sell
Current Market Cap: €117.4M
Find detailed analytics on IPH stock on TipRanks’ Stock Analysis page.